Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-127-4 | CAS number: 116-15-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 Oct 2017 to 31 Oct 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- January 2001
- Deviations:
- no
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD Guideline for Testing of Chemicals 412. Subacute Toxicity: 28-Day Study.
- Version / remarks:
- September 2009
- Deviations:
- yes
- Remarks:
- Ony used for the inhalation exposure part.
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Hexafluoropropene
- EC Number:
- 204-127-4
- EC Name:
- Hexafluoropropene
- Cas Number:
- 116-15-4
- Molecular formula:
- C3F6
- IUPAC Name:
- 1,1,2,3,3,3-hexafluoroprop-1-ene
- Test material form:
- gas under pressure: liquefied gas
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Wistar Han IGS rats (Crl:WI(Han)) (SPF)
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany.
- Age at study initiation: 10 weeks females and 9 weeks male upon arrival.
- Weight at study initiation: Group averages were between 200.89 and 208.06 g.
- Fasting period before study: No
- Housing: The animals were housed under conventional conditions in one animal room. No other test system was housed in the same room during the study. During the exposure periods, the rats were individually housed in the exposure unit. When not exposed, animals were housed in macrolon cages with a bedding of wood shavings (Lignocel) and strips of paper (Enviro-dri) and a wooden block as environmental enrichment. During the premating period, the rats were housed in groups of four per cage, separated by sex.
- Diet: ad libitum, cereal-based (closed formula) rodent diet (VRF1 (FG)) (SDS Special Diets Services, Witham, England)
- Water: ad libitum, tap-water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 24
- Humidity (%): 29.4 to 65
- Air changes (per hr): about 10
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES:
16 Oct 2017 to 31 Oct 2017
Administration / exposure
- Route of administration:
- inhalation: gas
- Type of inhalation exposure (if applicable):
- whole body
- Vehicle:
- clean air
- Remarks:
- HEPA filter
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: The animals were exposed to the test atmosphere in 2.2 m3 whole body exposure units (based on the design by Hazleton Systems, Inc., Aberdeen, MD, USA). The test atmosphere was introduced at the top and exhausted at the bottom of the chamber. During exposure, animals were housed individually in Type II Macrolon cages. Each whole body chamber could accommodate 60 cages. Animals were rotated at least twice weekly with respect to their position in the exposure chamber.
- Method of holding animals in test chamber: Not applicable, the animals were exposed via whole body exposure.
- Source and rate of air: Clean air was available as a laboratory provided source of (non-pressurized) filtered air (HEPA filter).
- Method of conditioning air: The test atmospheres were generated by mixing a mass flow controlled (Bronkhorst Hi Tec, Ruurlo, The Netherlands) stream of gaseous test material with a controlled flow of clean air.
- System of generating particulates/aerosols: Not applicable, the test substance is a gas.
- Temperature, humidity, pressure in air chamber: Temperature of 22 ± 3°C and a relative humidity between 30 and 70%. Pressure in the air chamber was not reported.
- Air flow rate: The flow of test atmosphere was controlled using a constant volume valve and was measured in the exhaust of the exposure chamber using a KIMO air velocity sensor (type CTV110-AOD150; KIMO, Emerainville, France). The flow was continuously measured and recorded on a PC every minute using a CAN transmitter (G. Lufft Mess- und Regeltechnik GmbH, 70719 Felbach, Germany).
- Air change rate: at least 10 air changes per hour
- Method of particle size determination: Not applicable
- Treatment of exhaust air: Not reported
TEST ATMOSPHERE
- Brief description of analytical method used: The actual concentration of the test material in the test atmospheres was measured by total carbon analysis (Sick Maihak GMS 810 EuroFID Total Hydrocarbon Analyzer; Sick Instruments Benelux, Hedel, the Netherlands). Test atmosphere samples were taken continuously from the exposure chamber at the animals’ breathing zone and were passed to the total carbon analyser (TCA) through a sample line. The response of the analyzers was recorded on a PC at one minute intervals using a CAN transmitter (G. Lufft Mess- und Regeltechnik GmbH, 70719 Felbach, Germany). The responses of the analyzers were converted to concentrations by means of calibration graphs.
- Samples taken from breathing zone: Yes
VEHICLE
- Clean air - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- ANALYTICAL VERIFICATION
Prior to the first exposure of the animals, homogeneous distribution of the test material in the exposure chambers was confirmed by analysis of samples taken at five different locations in each exposure chamber. Further details are described in the field ‘Details on exposure’.
CALIBRATION OF EQUIPMENT
Prior to the first exposure, the output of the flame ionization detector of each TCA was calibrated using gas sample bags. To this end, sample bags were filled with accurate (mass flow controlled) volumes of air; mass flow controlled streams of test material were added using a digital timer (Omron H5CX) and a valve system. The mass flow controller was calibrated using a volumetric flow meter (DryCal, Bios International Corporation, Butler, NJ, USA) at the flow settings used for filling of the sample bags. Three concentrations were thus prepared (in duplicate) – at approximately 80%, 100% and 120% of the target concentration of each group. A zero calibration was included for each TCA, using clean dry air only. Linear relations were found between the response of the analyzers and the concentration of the test material.
The calibrations were checked weekly during the study. To this end, gas sample bags were prepared at each target concentration as described above, and were subsequently analyzed by the TCA. If the measured concentration deviated more than 5% from the calculated concentration, the calibration check was repeated. If the deviation was more than 5% at the re-check, a complete re-calibration was carried out. - Details on mating procedure:
- - Impregnation procedure: cohoused
- M/F ratio per cage: 1/2
- Length of cohabitation: Animals were caged together until mating occurred.
- After 7 days of unsuccessful pairing replacement of first male by another male with proven fertility.
- Further matings after two unsuccessful attempts: No
- Verification of same strain and source of both sexes: Yes
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- Any other deviations from standard protocol: No - Duration of treatment / exposure:
- 6 hours per exposure
- Frequency of treatment:
- Daily
- Duration of test:
- Gestation day 6 up to and including day 20
Doses / concentrationsopen allclose all
- Dose / conc.:
- 50 ppm (nominal)
- Remarks:
- Group 2 (low dose)
- Dose / conc.:
- 300 ppm (nominal)
- Remarks:
- Group 3 (mid dose)
- Dose / conc.:
- 900 ppm (nominal)
- Remarks:
- Group 4 (high dose)
- No. of animals per sex per dose:
- 24 females per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The exposure levels were selected on the basis of the results of a range finding study with HFP in rats. Concentrations of 450 and 900 ppm showed effects on maternal body weight and food intake and induced clinical signs (piloerection). Based on these results 900 ppm was selected as high concentration in the current study and is anticipated to induce some maternal toxicity. The low concentration of 50 ppm was selected aiming to result in a No Observed Adverse Effect Concentration (NOAEC).
- Animal assignment: Random, in such a way that the animals from the same day of pregnancy were equally distributed over all groups. Females mated by the same male were placed in different groups.
Examinations
- Maternal examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily in the morning hours (pre-dosing) and halfway through the 6-hour exposure period (focussing on breathing abnormalities and restlessness).
- Cage side observations checked in Table 1 in ‘Any other information on materials and methods incl. tables’ were included.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily, after exposure.
BODY WEIGHT: Yes
- Time schedule for examinations: Body weights of the parental female animals was recorded on gestation days (GD) 0, 6, 9, 12, 15, 18 and 21.
FOOD CONSUMPTION: Yes
- Time schedule for food consumption recordings: The food consumed for each mated female was measured over the periods: GD 0-6, GD 6-9, GD 9-12, GD 12-15, GD 15-18 and GD 18-21.
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/per animal/day: Yes
WATER CONSUMPTION: No
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs weighed: Kidneys, liver, lungs, gravid uterus, empty uterus, ovaries, live fetuses (individually) with corresponding placentas.
- Organs preserved in neutral aqueous phosphate-buffered 4% solution of formaldehyde for possible future histopathological examinations: Lungs, liver, kidneys, gross lesions. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
- Other: Number of live and dead fetuses, sex of fetuses, number of grossly visible malformed fetuses and fetuses with external abnormalities, gross evaluation of placentas, abnormal tissues of organs in dams. - Fetal examinations:
- - External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: No - Statistics:
- Tests were generally performed as two-sided tests with results taken as significant where the probability of the results is p<0.05 (*) or p<0.01 (**). The statistical tests that were selected are presented in the data tables in ‘Any other information on results incl. tables’.
- Indices:
- For each litter the following data is presented for each group:
- Number of pregnant females
- Number of females with liveborn and (all) stillborn pups
- Post-implantation loss = [(number of implantation sites- number of live fetuses)/number of implantation sites] x 100
- Gestation index = (number of females with live fetuses / number of females pregnant) x 100
- Sex ratio = [(number of live male fetuses / number of live fetuses)] x 100 - Historical control data:
- -
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- PRE-DOSING SIGNS
The signs observed pre-exposure comprised skin observations (encrustations and sparsely haired areas) that are common in this rat strain, and based on the distribution amongst the groups not related to treatment. One animal in the 50 ppm group had encrustations in the eye, which is considered not related to treatment. However, animals in the high dose group (900 ppm) showed more piloerection (8 animals) and erythema of the ears (2 animals) compared to the controls (0 animals). These effects are considered related to treatment.
SIGNS DURING EXPOSURE
Observation of the animals about halfway through the 6-hour exposure period revealed piloerection in animals of the mid- and high-concentration groups. In animals of the mid concentration group, this finding was observed in all animals on 19, 20, 30 October and 2 November 2017 (and in several animals on 18 and 23 October 2017). In animals of the high concentration group, piloerection was seen in all animals on 19-25, 27, 30, 31 October and 2 November 2017, and in several animals on 17, 18 and 26 October 2017.
POST-DOSING SIGNS
The signs observed post-exposure comprised skin observations (encrustations and sparsely haired areas) that are common in this rat strain, and based on the distribution amongst the groups not related to treatment. However, 1 animal in the mid dose group and 14 animals in the high dosage group showed piloerection. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Body weight or body weight change were observed in the mid, and high concentration groups (Table 1 and 2 in 'Any other information on results incl. tables'). Significantly, but slightly (less than 5% as compared to the control group) lower body weight was observed from gestation day 15 onwards in the 300 ppm group. In the 900 ppm group statistically significant lower body weight of approximately 15% as compared to the control group were observed from gestation day 9 onwards.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- Concentration related lowered mean food consumption was observed in the mid and high concentration groups for intervals 6-9 days and later (Table 3 in 'Any other information on results incl. tables').
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- A lower full uterus weight (including fetal and placental tissues) was observed in the high concentration group. Similarly, significantly lower empty uterus weight was found in the mid and high concentration groups. No differences were observed for ovary weight (Table 5 in 'Any other information on results incl. tables').
Terminal body weight was significantly lower in the mid and high concentration groups (Table 6 in 'Any other information on results incl. tables'). Mean absolute kidney weight was significantly higher already at the 50 ppm level. When expressed relatively to body weight this was observed only for the 300 and 900 ppm groups. No differences were observed in liver weight. Mean absolute lung weights were higher in the high concentration group. When this parameter was expressed relatively to body weight this was observed already at the 300 ppm level.
No effects on mean placenta weight were observed in all concentration groups (Table 7 in 'Any other information on results incl. tables'). - Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Several animals in the high concentration group showed discoloration of the kidneys. This was considered to be related to treatment and in combination with the effects on kidney weight considered adverse.
No other treatment-related macroscopic changes were observed. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
Maternal developmental toxicity
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- no effects observed
- Description (incidence and severity):
- The mean number of corpora lutea (13.8, 13.4, 14.0 and 13.6 for the control, low, mid and high concentration group, respectively) and the mean number of implantation sites (12.4, 12.4, 12.5, and 11.9 for the control, low, mid and high concentration group, respectively) were comparable in all groups. Similarly, no differences in mean pre-implantation loss were observed (Table 4 in 'Any other information on results incl. tables').
Mean post-implantation loss was comparable over all groups (3.70, 3.86, 5.98 and 4.88 % in the control, low, mid and high concentration groups, respectively, Table 4 in 'Any other information on results incl. tables'). - Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- The mean number of early resorptions per litter (0.3, 0.4, 0.7, and 0.6 for the control, low, mid and high concentration groups, respectively) and the number of late resorptions per litter (0.1, 0.0, 0.0, and 0.0 for the control, low, mid and high concentration groups, respectively) were comparable in all groups (Table 4 in 'Any other information on results incl. tables'.).
- Dead fetuses:
- no effects observed
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- no effects observed
- Other effects:
- not examined
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- food consumption and compound intake
- gross pathology
- organ weights and organ / body weight ratios
Maternal abnormalities
- Key result
- Abnormalities:
- no effects observed
Results (fetuses)
- Fetal body weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A slightly, but statistically significantly lower mean fetal weight was observed in the 300 ppm group (less than 5% lower as compared to the control group, Table 7 in 'Any other information on results incl. tables'). This was considered treatment-related, but not biologically adverse.
Significantly lower mean fetal weight was observed in the 900 ppm groups (more than 15% lower as compared to the control group). This was considered a treatment-related and adverse effect. - Reduction in number of live offspring:
- no effects observed
- Changes in sex ratio:
- no effects observed
- Changes in litter size and weights:
- no effects observed
- Changes in postnatal survival:
- no effects observed
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- MALFORMATIONS (Table 8 in 'Any other information on results incl. tables')
There were no treatment-related external malformations.
VARIATIONS
Based on the number and distribution of the variations observed there were no treatment-related effects. - Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- MALFORMATIONS (Table 10 in 'Any other information on results incl. tables')
No treatment-related skeletal malformations were found.
VARIATIONS
Multiple skeletal variations indicative for retardation in ossification were noted. With some exceptions, statistical significance was mostly confined to the high-concentration group. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- MALFORMATIONS (Table 9 in 'Any other information on results incl. tables')
No fetal visceral malformations were observed.
VARIATIONS
Although several visceral observations were made, their incidence was not statistically different in any concentration group.
Based on the above incidences of malformations and variations, it was concluded that visceral examination did not reveal any treatment-related effects. - Other effects:
- not examined
Effect levels (fetuses)
- Key result
- Dose descriptor:
- NOAEC
- Effect level:
- 300 ppm (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- other: Retarded ossification
Fetal abnormalities
- Key result
- Abnormalities:
- no effects observed
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 900 ppm (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Any other information on results incl. tables
Actual concentrations in the exposure chambers: The overall average actual concentrations (± standard deviation) of test substance in the test atmospheres, as determined by total carbon analysis, were 50 (± 0.7), 302 (± 3) and 901 (± 16) ppm for the low-, mid- and high-concentration, respectively. These concentrations were close to the respective target concentrations of 50, 300 and 900 ppm.
Table 1. Body weight gestation – Day(s) relative to mating
Sex: Female |
Bodyweights |
|||||||
Bodywt
(g)
[G] |
Bodywt
(g)
[G1] |
Bodywt
(g)
[G] |
Bodywt
(g)
[G] |
Bodywt
(g)
[G] |
Bodywt
(g)
[G] |
Bodywt
(g)
[G1] |
||
0 |
6 |
9 |
12 |
15 |
18 |
21 |
||
0 ppm |
Mean SD N |
202.48 7.68 23 |
227.67 9.71 23 |
235.57 10.35 23 |
247.35 10.61 23 |
259.85 10.84 23 |
289.24 13.59 23 |
318.51 23.26 23 |
50 ppm |
Mean SD N |
206.72 8.66 22 |
230.75 9.92 22 |
237.72 10.90 22 |
250.30 11.13 22 |
261.21 11.38 22 |
289.20 11.96 22 |
324.82 15.35 22 |
300 ppm |
Mean SD N |
208.06 7.45 23 |
231.05 12.35 23 |
231.04 8.45 23 |
240.07 9.72 23 |
248.50 ** 10.27 23 |
277.32 ** 11.97 23 |
307.31 * 14.40 23 |
900 ppm |
Mean SD N |
200.89 8.40 21 |
226.90 9.91 21 |
214.31 ** 10.13 21 |
219.93 ** 11.43 21 |
232.82 ** 11.55 21 |
255.10 ** 12.40 21 |
272.31 ** 25.96 21 |
[G] - Ancova/Anova & Dunnett: ** = p < 0.01
[G1] - Kruskal-Wallis & Dunnett on Ranks: * = p < 0.05; ** = p < 0.01
Table 2. Body weight changes gestation – Day(s) relative to mating
Sex: Female |
|
||||||
Body wt change (g)
[g] |
Body wt change (g)
[g] |
Body wt change (g)
[g] |
Body wt change (g)
[g1] |
Body wt change (g)
[g1] |
Body wt change (g)
[g] |
||
0 - 6 |
6 - 9 |
9 - 12 |
12 - 15 |
15 - 18 |
18 - 21 |
||
0 ppm |
Mean SD N |
25.19 4.71 23 |
7.89 2.21 23 |
11.78 2.59 23 |
12.50 3.42 23 |
29.39 3.97 23 |
29.27 14.62 23 |
50 ppm |
Mean SD N |
24.02 4.85 22 |
6.98 3.58 22 |
12.58 2.38 22 |
10.91 3.85 22 |
27.99 4.15 22 |
35.63 7.31 22 |
300 ppm |
Mean SD N |
23.00 7.72 23 |
-0.01 ** 6.85 23 |
9.03 ** 3.05 23 |
8.43 ** 5.24 23 |
28.82 5.14 23 |
29.99 5.49 23 |
900 ppm |
Mean SD N |
26.01 5.45 21 |
-12.58 ** 5.52 21 |
5.62 ** 4.60 21 |
12.89 3.62 21 |
22.29 ** 3.03 21 |
17.21 ** 22.91 21 |
[g] - Kruskal-Wallis & Dunnett on Ranks: ** = p < 0.01
[g1] - Anova & Dunnett: ** = p < 0.01
Table 3. Food consumption – Day(s) relative to mating
Sex: Female |
Day(s) Relative to Mating (Litter: A) |
||||||
0 - 6 |
6 - 9 |
9 - 12 |
12 - 15 |
15 - 18 |
18 - 21 |
||
0 ppm |
Mean SD N |
16.29 1.68 23 |
16.86 1.50 23 |
18.12 1.32 23 |
18.18 1.06 23 |
21.27 2.23 23 |
18.63 1.96 23 |
50 ppm |
Mean SD N |
16.09 1.18 22 |
16.70 1.52 22 |
17.88 1.40 22 |
18.05 2.05 22 |
19.89 2.38 22 |
19.01 1.84 22 |
300 ppm |
Mean SD N |
16.07 1.47 23 |
14.19 ** 1.07 23 |
15.01 ** 1.50 23 |
16.08 ** 1.93 23 |
18.59 ** 1.69 23 |
17.64 2.40 23 |
900 ppm |
Mean SD N |
16.57 1.60 21 |
9.29 ** 2.63 21 |
10.83 ** 2.45 21 |
15.24 ** 1.84 21 |
16.27 ** 2.23 21 |
14.90 ** 2.92 21 |
Dunnett: ** = p < 0.01
N=Number of cages
Consumption was measured per cage over the periods shown and expressed as g/animal/day
Table 4. Cesarean section
Sex: Female |
0 ppm |
50 ppm |
300 ppm |
900 ppm |
|
Females Mated [f] |
N+ve |
24 |
24 |
24 |
24 |
Pregnant at C-section |
N+ve |
23 |
22 |
23 |
21 |
Not Pregnant at C-section |
N+ve |
1 |
2 |
1 |
3 |
Females Delivered Early |
N+ve |
0 |
0 |
0 |
0 |
Dams with no viable Fetuses |
N+ve |
0 |
0 |
0 |
0 |
Dams with live Fetuses |
N+ve |
23 |
22 |
23 |
21 |
Female Fecundity Index |
% |
95.8 |
91.7 |
95.8 |
87.5 |
Gestation Index |
% |
100.0 |
100.0 |
100.0 |
100.0 |
Number of Corpora Lutea [k] |
Mean |
13.8 |
13.4 |
14.0 |
13.6 |
|
SD |
1.8 |
1.7 |
1.6 |
2.0 |
|
N |
23 |
22 |
23 |
21 |
|
Sum |
317 |
294 |
322 |
285 |
Number of Implantation Sites [k] |
Mean |
12.4 |
12.4 |
12.5 |
11.9 |
|
SD |
1.6 |
1.7 |
1.6 |
3.0 |
|
N |
23 |
22 |
23 |
21 |
|
Sum |
286 |
272 |
287 |
249 |
Pre-implantation Loss (%) |
Mean |
9.49 |
7.68 |
10.13 |
13.30 |
|
SD |
7.47 |
8.01 |
12.10 |
17.84 |
|
N |
23 |
22 |
23 |
21 |
Number of Live Fetuses [k] |
Mean |
12.0 |
11.9 |
11.7 |
11.2 |
|
SD |
1.7 |
2.1 |
1.7 |
2.7 |
|
Sum |
275 |
262 |
269 |
235 |
Post-implantation Loss (%) [k] |
Mean |
3.70 |
3.86 |
5.98 |
4.88 |
|
SD |
7.34 |
10.13 |
9.35 |
8.20 |
|
N |
23 |
22 |
23 |
21 |
Number of Dead Fetuses [k] |
Mean |
0.0 |
0.0 |
0.0 |
0.1 |
|
SD |
0.0 |
0.0 |
0.2 |
0.4 |
|
Sum |
0 |
0 |
1 |
2 |
Number of Resorptions: Total [k] |
Mean |
0.5 |
0.5 |
0.7 |
0.6 |
|
SD |
1.0 |
1.1 |
1.2 |
1.1 |
|
N |
23 |
22 |
23 |
21 |
|
Sum |
11 |
10 |
17 |
12 |
Number of Resorptions: Early [k] |
Mean |
0.3 |
0.4 |
0.7 |
0.6 |
|
SD |
0.6 |
1.0 |
1.2 |
1.1 |
|
N |
23 |
22 |
23 |
21 |
|
Sum |
8 |
9 |
17 |
12 |
Number of Resorptions: Late [k] |
Mean |
0.1 |
0.0 |
0.0 |
0.0 |
|
SD |
0.6 |
0.2 |
0.0 |
0.0 |
|
N |
23 |
22 |
23 |
21 |
|
Sum |
3 |
1 |
0 |
0 |
Live Male Fetuses [f] |
Mean SD N Sum
Mean SD N Sum |
6.5 2.1 23 150 54.5 5.4 1.7 23 125 45.5 |
6.1 1.9 22 135 51.7 5.7 1.8 22 126 48.3 |
5.6 1.5 23 128 47.6 6.1 1.7 23 141 52.4 |
5.5 2.1 21 115 48.9 5.7 2.2 21 120 51.1 |
Sex Ratio - Male Fetuses (%) |
|||||
Live Female Fetuses [f] |
|||||
Sex Ratio - Female Fetuses (%) |
[f] - Chi-Squared & Fisher’s Exact
[k] - Kruskal-Wallis & Wilcoxon
Pre-implantation loss: no. corpora lutea - no. implant sites *100/no. corpora lutea
Post-implantation loss: no. implant sites - no. live fetuses *100/no. implant sites
Sex ratio: no. of live (fe)male fetuses *100/ no. of live fetuses
Female fecundity index: no. of females pregnant * 100 /no. of females mated
Gestation index: no. of females with live fetuses * 100 /no. of females pregnant
Table 5. Reproductive organ weights – Day(s) relative to mating
Sex: Female |
|
|
|
|
Gravid Uterus (g)
[g] |
Uterus empty (g)
[g1] |
Ovaries (g)
[g1] |
||
21 |
21 |
21 |
||
0 ppm |
Mean |
78.6535 |
4.8273 |
0.1130 |
|
SD |
10.4029 |
0.6216 |
0.0152 |
|
N |
23 |
22 |
23 |
50 ppm |
Mean |
76.5664 |
4.5086 |
0.1147 |
|
SD |
11.3180 |
0.6201 |
0.0162 |
|
N |
22 |
22 |
22 |
300 ppm |
Mean |
74.0945 |
4.3251 * |
0.1153 |
|
SD |
11.1448 |
0.6968 |
0.0125 |
|
N |
22 |
23 |
23 |
900 ppm |
Mean |
63.3548 ** |
3.8294 ** |
0.1103 |
|
SD |
13.5118 |
0.6248 |
0.0127 |
|
N |
21 |
21 |
21 |
[g] - Kruskal-Wallis & Dunnett on Ranks: ** = p < 0.01
[g1] - Anova & Dunnett: * = p < 0.05; ** = p < 0.01
Table 6. Organ weights – Day(s) relative to mating
Sex: Female |
Bodyweights |
|
|
|
|
|
|
|
Bodywt
(g)
[G] |
Kidneys
(g)
[G] |
Liver
(g)
[G1] |
Lungs
(g)
[G1] |
Kidneys relative (g/kg body wgt) [G] |
Liver relative (g/kg body wgt) [G] |
Lungs relative (g/kg body wgt) [G] |
||
21 |
21 |
21 |
21 |
21 |
21 |
21 |
||
0 ppm |
Mean SD N |
318.51 23.26 23 |
1.333 0.130 23 |
10.133 1.046 23 |
1.107 0.091 23 |
4.196 0.405 23 |
31.87 2.97 23 |
3.485 0.308 23 |
50 ppm |
Mean SD N |
324.82 15.35 22 |
1.438 * 0.127 22 |
10.423 1.217 22 |
1.090 0.084 22 |
4.431 0.401 22 |
32.05 3.09 22 |
3.358 0.218 22 |
300 ppm |
Mean SD N |
307.31 * 14.40 23 |
1.477 ** 0.156 23 |
10.177 0.730 23 |
1.129 0.085 23 |
4.812 ** 0.495 23 |
33.16 2.55 23 |
3.678 * 0.284 23 |
900 ppm |
Mean SD N |
272.31 ** 25.96 21 |
1.737 ** 0.272 21 |
9.754 1.352 21 |
1.220 ** 0.092 21 |
6.424 ** 1.084 21 |
35.98 ** 5.25 21 |
4.526 ** 0.607 21 |
[G] - Kruskal-Wallis & Dunnett on Ranks: * = p < 0.05; ** = p < 0.01
[G1] - Ancova/Anova & Dunnett: ** = p < 0.01
Table 7. Placental and fetal weight – Day(s) relative to mating
Sex: Female |
|
|
|
|
|
|
|
Placental wt (M) mean (g)
[g] |
Placental wt (F) mean (g)
[g1] |
Placental wt (M+F) mean (g)
[g1] |
Fetal wt (M) mean (g)
[g] |
Fetal wt (F) mean (g)
[g] |
Fetal wt (M+F) mean (g)
[g] |
||
21 |
21 |
21 |
21 |
21 |
21 |
||
0 ppm |
Mean SD N |
0.464 0.048 23 |
0.436 0.049 23 |
0.453 0.045 23 |
5.108 0.232 23 |
4.848 0.226 23 |
4.995 0.212 23 |
50 ppm |
Mean SD N |
0.462 0.051 22 |
0.422 0.045 22 |
0.443 0.047 22 |
4.974 0.250 22 |
4.694 0.225 22 |
4.842 0.233 22 |
300 ppm |
Mean SD N |
0.452 0.047 23 |
0.433 0.050 23 |
0.444 0.048 23 |
4.860 * 0.312 23 |
4.608 ** 0.262 23 |
4.728 ** 0.278 23 |
900 ppm |
Mean SD N |
0.460 0.067 20 |
0.442 0.075 21 |
0.458 0.075 21 |
4.239 ** 0.340 20 |
4.045 ** 0.351 21 |
4.162 ** 0.350 21 |
[g] - Anova & Dunnett: * = p < 0.05; ** = p < 0.01
[g1] - Anova & Dunnett(Log)
Table 8. Fetal external observations
Exam Type: External |
Number of Fetuses Examined: Number of Litters Examined: |
0 ppm |
50 ppm |
300 ppm |
900 ppm |
|
275 23 |
262 22 |
269 23 |
2241 201 |
|||
Eye |
|
|
|
|
|
|
Eye bulge, Protruding - Variation |
Fetuses N(%) |
1(0.4) |
0(0.0) |
0(0.0) |
0(0.0) |
|
|
Litters N(%) |
1(4.3) |
0(0.0) |
0(0.0) |
0(0.0) |
|
General |
|
|
|
|
|
|
General, Pale - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(0.4) |
|
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(5.0) |
|
General, Small - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.4) |
1(0.4) |
|
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
1(5.0) |
|
General, Subcutaneous hemorrhage - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(0.4) |
|
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(5.0) |
|
Localized, Subcutaneous hemorrhage - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(0.4) |
|
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(5.0) |
|
Head/Neck |
|
|
|
|
|
|
Head, Small - Variation |
Fetuses N(%) |
1(0.4) |
0(0.0) |
0(0.0) |
0(0.0) |
|
|
Litters N(%) |
1(4.3) |
0(0.0) |
0(0.0) |
0(0.0) |
|
Jaw,lower, Absent - Malformation |
Fetuses N(%) |
1(0.4) |
0(0.0) |
0(0.0) |
0(0.0) |
|
|
Litters N(%) |
1(4.3) |
0(0.0) |
0(0.0) |
0(0.0) |
|
Trunk |
|
|
|
|
|
|
Umbilicus, Hernia - Malformation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.4) |
0(0.0) |
|
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
1 = Erroneously no external observations were recorded for one animal
[Fetuses N] - Chi-Squared & Fisher's Exact
[Litters N] - Chi-Squared & Fisher's Exact
Table 9. Fetal visceral observations
Exam Type: Visceral
|
Number of Fetuses Examined: Number of Litters Examined: |
0 ppm |
50 ppm |
300 ppm |
900 ppm |
|
132 23 |
128 22 |
129 23 |
111 21 |
|||
Eye |
|
|
|
|
|
|
Retina, Fold - Variation |
Fetuses N(%) |
2(1.5) |
6(4.7) |
6(4.7) |
5(4.5) |
|
|
Litters N(%) |
2(8.7) |
5(22.7) |
5(21.7) |
4(19.0) |
|
Liver |
|
|
|
|
|
|
Lobe, Supernumerary - Variation |
Fetuses N(%) |
1(0.8) |
0(0.0) |
0(0.0) |
0(0.0) |
|
|
Litters N(%) |
1(4.3) |
0(0.0) |
0(0.0) |
0(0.0) |
|
Ureter |
|
|
|
|
|
|
Ureter, Bent - Variation |
Fetuses N(%) |
14(10.6) |
8(6.3) |
5(3.9) |
6(5.4) |
|
|
Litters N(%) |
11(47.8) |
5(22.7) |
5(21.7) |
6(28.6) |
|
Ureter, Dilated - Variation |
Fetuses N(%) |
0(0.0) |
1(0.8) |
0(0.0) |
0(0.0) |
|
|
Litters N(%) |
0(0.0) |
1(4.5) |
0(0.0) |
0(0.0) |
|
Ureter, Kinked - Variation |
Fetuses N(%) |
5(3.8) |
7(5.5) |
5(3.9) |
6(5.4) |
|
|
Litters N(%) |
5(21.7) |
6(27.3) |
3(13.0) |
4(19.0) |
|
Urinary Bladder |
|
|
|
|
|
|
Bladder, Distended - Variation |
Fetuses N(%) |
2(1.5) |
3(2.3) |
2(1.6) |
2(1.8) |
|
|
Litters N(%) |
2(8.7) |
3(13.6) |
2(8.7) |
1(4.8) |
|
[Fetuses N] - Chi-Squared & Fisher's Exact
[Litters N] - Chi-Squared & Fisher's Exact
Table 10. Fetal skeletal observations
Exam Type: Skeletal |
Number of Fetuses Examined: Number of Litters Examined: |
0 ppm |
50 ppm |
300 ppm |
900 ppm |
||
141 23 |
133 22 |
139 23 |
124 21 |
||||
Vertebra, caudal |
|
|
|
|
|
||
Caudal bodies, one or two, Unossified - Variation |
Fetuses N(%) |
30(21.3) |
35(26.3) |
53(38.4)** |
57(46.0)** |
||
|
Litters N(%) |
12(52.2) |
13(59.1) |
16(69.6) |
15(71.4) |
||
Caudal bodies, three or more, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Caudal arches, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
19(13.5) |
23(17.3) |
16(11.6) |
10(8.1) |
||
|
Litters N(%) |
8(34.8) |
8(36.4) |
7(30.4) |
6(28.6) |
||
Caudal arches, one or two, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
4(3.0) |
0(0.0) |
6(4.8)** |
||
|
Litters N(%) |
0(0.0) |
3(13.6) |
0(0.0) |
4(19.0)* |
||
Caudal arches, three or more, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(0.8) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(4.8) |
||
Vertebra, cervical |
|
|
|
|
|
||
Cervical bodies, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
1(0.7) |
1(0.8) |
2(1.4) |
2(1.6) |
||
|
Litters N(%) |
1(4.3) |
1(4.5) |
2(8.7) |
2(9.5) |
||
Cervical bodies, one or two, Unossified - Variation |
Fetuses N(%) |
2(1.4) |
2(1.5) |
3(2.2) |
9(7.3)* |
||
|
Litters N(%) |
2(8.7) |
2(9.1) |
1(4.3) |
7(33.3) |
||
Cervical bodies, three or more, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
2(1.6) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(4.8) |
||
Cervical bodies, three or more, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
12(9.7)** |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
9(42.9)** |
||
Vertebra, lumbar |
|
|
|
|
|
||
Lumbar bodies, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
1(0.7) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
1(4.3) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Lumbar arches, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
8(5.7) |
13(9.8) |
3(2.2) |
0(0.0)** |
||
|
Litters N(%) |
6(26.1) |
9(40.9) |
2(8.7) |
0(0.0)* |
||
Pelvic girdle |
|
|
|
|
|
||
Pubis, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
Pubis, Incomplete ossification - Variation |
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Rib |
|
|
|
|
|
||
One Rib, Wavy - Variation |
Fetuses N(%) |
4(2.8) |
2(1.5) |
0(0.0) |
1(0.8) |
||
|
Litters N(%) |
2(8.7) |
2(9.1) |
0(0.0) |
1(4.8) |
||
Two Ribs, Wavy - Variation |
Fetuses N(%) |
10(7.1) |
11(8.3) |
3(2.2) |
5(4.0) |
||
|
Litters N(%) |
5(21.7) |
5(22.7) |
3(13.0) |
3(14.3) |
||
Three or more Ribs, Wavy - Variation |
Fetuses N(%) |
3(2.1) |
3(2.3) |
4(2.9) |
10(8.1)* |
||
|
Litters N(%) |
2(8.7) |
3(13.6) |
4(17.4) |
6(28.6) |
||
Vertebra, sacral |
|
|
|
|
|
||
Sacral bodies, one or two, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
3(2.4) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
3(14.3) |
||
Sacral arches, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
2(1.4) |
1(0.8) |
0(0.0) |
0(0.0) |
||
|
Litters N(%) |
1(4.3) |
1(4.5) |
0(0.0) |
0(0.0) |
||
Skull |
|
|
|
|
|
||
Hyoid, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
2(1.5) |
0(0.0) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
1(4.5) |
0(0.0) |
0(0.0) |
||
Interparietal, Incomplete ossification - Variation |
Fetuses N(%) |
5(3.5) |
13(9.8)* |
13(9.4) |
20(16.1)** |
||
|
Litters N(%) |
4(17.4) |
8(36.4) |
8(34.8) |
8(38.1) |
||
Mandible, Hole - Variation |
Fetuses N(%) |
4(2.8) |
4(3.0) |
4(2.9) |
6(4.8) |
||
|
Litters N(%) |
3(13.0) |
3(13.6) |
2(8.7) |
3(14.3) |
||
Mandible, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(0.8) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
1(4.8) |
||
Nasal, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Parietal, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
8(6.0)** |
7(5.0)** |
17(13.7)** |
||
|
Litters N(%) |
0(0.0) |
4(18.2) |
4(17.4) |
4(19.0) |
||
Supraoccipital, Hole - Variation |
Fetuses N(%) |
1(0.7) |
3(2.3) |
1(0.7) |
2(1.6) |
||
|
Litters N(%) |
1(4.3) |
3(13.6) |
1(4.3) |
2(9.5) |
||
Supraoccipital, Incomplete ossification - Variation |
Fetuses N(%) |
5(3.5) |
21(15.8)** |
18(12.9)** |
28(22.6)** |
||
|
Litters N(%) |
4(17.4) |
12(54.5)* |
10(43.5) |
12(57.1)* |
||
Frontal, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
4(3.0) |
5(3.6)* |
12(9.7)** |
||
|
Litters N(%) |
0(0.0) |
3(13.6) |
2(8.7) |
4(19.0) |
||
Squamosal, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
2(1.6) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
2(9.5) |
||
Zygomatic arch, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
1(0.8) |
3(2.2) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
1(4.5) |
1(4.3) |
0(0.0) |
||
Sternebra |
|
|
|
|
|
||
One Sternebra, Bipartite ossification - Variation |
Fetuses N(%) |
1(0.7) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
1(4.3) |
0(0.0) |
1(4.3) |
0(0.0) |
||
One Sternebra, Dumbbell ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
2(1.6) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
0(0.0) |
2(9.5) |
||
One Sternebra, Incomplete ossification - Variation |
Fetuses N(%) |
71(50.4) |
66(49.6) |
78(56.1) |
51(41.1) |
||
|
Litters N(%) |
23(100.0) |
21(95.5) |
22(95.7) |
18(85.7) |
||
One Sternebra, Irregularly ossified - Variation |
Fetuses N(%) |
1(0.7) |
1(0.8) |
0(0.0) |
0(0.0) |
||
|
Litters N(%) |
1(4.3) |
1(4.5) |
0(0.0) |
0(0.0) |
||
One Sternebra, Irregularly shaped - Variation |
Fetuses N(%) |
21(14.9) |
19(14.3) |
21(15.1) |
17(13.7) |
||
|
Litters N(%) |
13(56.5) |
13(59.1) |
13(56.5) |
11(52.4) |
||
Two Sternebrae, Dumbbell ossification - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Two Sternebrae, Incomplete ossification - Variation |
Fetuses N(%) |
7(5.0) |
6(4.5) |
10(7.2) |
28(22.6)** |
||
|
Litters N(%) |
4(17.4) |
6(27.3) |
9(39.1) |
13(61.9)** |
||
Two Sternebrae, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
Two Sternebrae, Unossified - Variation |
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Two Sternebrae, Irregularly shaped - Variation |
Fetuses N(%) |
14(9.9) |
9(6.8) |
9(6.5) |
16(12.9) |
||
|
Litters N(%) |
5(21.7) |
8(36.4) |
7(30.4) |
9(42.9) |
||
Three or more Sternebrae, Incomplete ossification - Variation |
Fetuses N(%) |
1(0.7) |
0(0.0) |
0(0.0) |
3(2.4) |
||
|
Litters N(%) |
1(4.3) |
0(0.0) |
0(0.0) |
2(9.5) |
||
Three or more Sternebrae, Irregularly shaped - Variation |
Fetuses N(%) |
5(3.5) |
4(3.0) |
12(8.6) |
7(5.6) |
||
|
Litters N(%) |
5(21.7) |
4(18.2) |
9(39.1) |
4(19.0) |
||
Vertebra, thoracic |
|
|
|
|
|
||
Thoracic bodies, one or two, Asymmetric ossification - Variation |
Fetuses N(%) |
1(0.7) |
0(0.0) |
2(1.4) |
0(0.0) |
||
|
Litters N(%) |
1(4.3) |
0(0.0) |
2(8.7) |
0(0.0) |
||
Thoracic bodies, one or two, Incomplete ossification - Variation |
Fetuses N(%) |
7(5.0) |
18(13.5) |
16(11.5) |
11(8.9) |
||
|
Litters N(%) |
6(26.1) |
11(50.0) |
9(39.1) |
4(19.0) |
||
Thoracic bodies, three or more, Incomplete ossification - Variation |
Fetuses N(%) |
2(1.4) |
3(2.3) |
1(0.7) |
1(0.8) |
||
|
Litters N(%) |
2(8.7) |
3(13.6) |
1(4.3) |
1(4.8) |
||
Supernumerary rib |
|
|
|
|
|
||
Thoracolumbar, Full - Variation |
Fetuses N(%) |
7(5.0) |
8(6.0) |
1(0.7) |
10(8.1) |
||
|
Litters N(%) |
5(21.7) |
5(22.7) |
1(4.3) |
8(38.1) |
||
Thoracolumbar, Long - Variation |
Fetuses N(%) |
4(2.8) |
1(0.8) |
0(0.0) |
0(0.0) |
||
|
Litters N(%) |
2(8.7) |
1(4.5) |
0(0.0) |
0(0.0) |
||
Thoracolumbar, Short - Variation |
Fetuses N(%) |
81(57.4) |
69(51.9) |
75(54.0) |
64(51.6) |
||
|
Litters N(%) |
20(87.0) |
17(77.3) |
23(100.0) |
19(90.5) |
||
Forelimb, phalanges proximal |
|
|
|
|
|
||
1-4 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
53(37.6) |
58(43.6) |
69(49.6) |
42(33.9) |
||
|
Litters N(%) |
20(87.0) |
21(95.5) |
18(78.3) |
16(76.2) |
||
1-4 Digits, Unossified - Variation |
Fetuses N(%) |
36(25.5) |
47(35.3) |
47(33.8) |
62(50.0)** |
||
|
Litters N(%) |
17(73.9) |
17(77.3) |
18(78.3) |
18(85.7) |
||
5-8 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
4(2.8) |
1(0.8) |
0(0.0) |
3(2.4) |
||
|
Litters N(%) |
2(8.7) |
1(4.5) |
0(0.0) |
2(9.5) |
||
5-8 Digits, Unossified - Variation |
Fetuses N(%) |
2(1.4) |
3(2.3) |
9(6.5)* |
15(12.1)** |
||
|
Litters N(%) |
1(4.3) |
3(13.6) |
5(21.7) |
6(28.6) |
||
Forelimb, phalanges distal |
|
|
|
|
|
||
1-5 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
14(9.9) |
22(16.5) |
19(13.7) |
19(15.3) |
||
|
Litters N(%) |
11(47.8) |
11(50.0) |
10(43.5) |
9(42.9) |
||
1-5 Digits, Unossified - Variation |
Fetuses N(%) |
12(8.5) |
14(10.5) |
17(12.2) |
23(18.5) |
||
|
Litters N(%) |
8(34.8) |
9(40.9) |
13(56.5) |
10(47.6) |
||
6-10 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
3(2.1) |
3(2.3) |
8(5.8) |
5(4.0) |
||
|
Litters N(%) |
2(8.7) |
3(13.6) |
6(26.1) |
4(19.0) |
||
6-10 Digits, Unossified - Variation |
Fetuses N(%) |
2(1.4) |
2(1.5) |
3(2.2) |
4(3.2) |
||
|
Litters N(%) |
2(8.7) |
2(9.1) |
3(13.0) |
3(14.3) |
||
Forelimb, metacarpal |
|
|
|
|
|
||
1-2 Metacarpals, Incomplete ossification - Variation |
Fetuses N(%) |
0(0.0) |
2(1.5) |
1(0.7) |
10(8.1)** |
||
|
Litters N(%) |
0(0.0) |
2(9.1) |
1(4.3) |
5(23.8)* |
||
1-2 Metacarpals, Unossified - Variation |
Fetuses N(%) |
0(0.0) |
0(0.0) |
1(0.7) |
0(0.0) |
||
|
Litters N(%) |
0(0.0) |
0(0.0) |
1(4.3) |
0(0.0) |
||
Hindlimb, metatarsal |
|
|
|
|
|
||
1-2 Metatarsals, Incomplete ossification - Variation |
Fetuses N(%) |
8(5.7) |
10(7.5) |
27(19.4)** |
15(12.1) |
||
|
Litters N(%) |
4(17.4) |
5(22.7) |
12(52.2)* |
9(42.9) |
||
1-2 Metatarsals, Unossified - Variation |
Fetuses N(%) |
1(0.7) |
1(0.8) |
10(7.2)** |
53(42.7)** |
||
|
Litters N(%) |
1(4.3) |
1(4.5) |
5(21.7) |
15(71.4)** |
||
Hindlimb, phalanges distal |
|
|
|
|
|
||
6-10 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
11(7.8) |
5(3.8) |
15(10.8) |
19(15.3) |
||
|
Litters N(%) |
5(21.7) |
2(9.1) |
7(30.4) |
4(19.0) |
||
6-10 Digits, Unossified - Variation |
Fetuses N(%) |
5(3.5) |
3(2.3) |
7(5.0) |
9(7.3) |
||
|
Litters N(%) |
3(13.0) |
2(9.1) |
4(17.4) |
6(28.6) |
||
1-5 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
6(4.3) |
7(5.3) |
17(12.2) |
10(8.1) |
||
|
Litters N(%) |
5(21.7) |
6(27.3) |
9(39.1) |
6(28.6) |
||
1-5 Digits, Unossified - Variation |
Fetuses N(%) |
6(4.3) |
7(5.3) |
14(10.1) |
8(6.5) |
||
|
Litters N(%) |
5(21.7) |
5(22.7) |
10(43.5) |
6(28.6) |
||
Hindlimb, phalanges proximal |
|
|
|
|
|
||
1-4 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
50(35.5) |
36(27.1) |
32(23.0)* |
6(4.8)** |
||
|
Litters N(%) |
17(73.9) |
16(72.7) |
13(56.5) |
4(19.0)** |
||
1-4 Digits, Unossified - Variation |
Fetuses N(%) |
43(30.5) |
39(29.3) |
34(24.5) |
11(8.9)** |
||
|
Litters N(%) |
19(82.6) |
20(90.9) |
15(65.2) |
8(38.1)** |
||
5-8 Digits, Incomplete ossification - Variation |
Fetuses N(%) |
16(11.3) |
17(12.8) |
17(12.2) |
6(4.8) |
||
|
Litters N(%) |
8(34.8) |
11(50.0) |
9(39.1) |
5(23.8) |
||
5-8 Digits, Unossified - Variation |
Fetuses N(%) |
41(29.1) |
52(39.1) |
83(59.7)** |
105(84.7)** |
||
|
Litters N(%) |
15(65.2) |
17(77.3) |
21(91.3) |
20(95.2)* |
[Fetuses N] - Chi-Squared & Fisher's Exact: * = p < 0.05; ** = p < 0.01
[Litters N] - Chi-Squared & Fisher's Exact: * = p < 0.05; ** = p < 0.01
Applicant's summary and conclusion
- Conclusions:
- In this GLP compliant OECD 414 study, the observed effects on body weight, feed intake and kidney weight (supported by macroscopic observations in the 900 ppm group) were considered related to treatment and adverse. Therefore, the No Observed Adverse Effect Concentration (NOAEC) for maternal toxicity was placed at 300 ppm. The effect on fetus weight, accompanied by a retardation in ossification observed in the 900 ppm group was considered adverse. Therefore NOAEC for developmental toxicity was placed at 300 ppm.
- Executive summary:
The objective of this GLP compliant OECD 414 study was to provide data on the possible effects of hexafluoropropene on pregnant female Wistar rats, and on the development of the embryo and fetus. The test material was administered by inhalation (whole body exposure) to groups of 24 mated females from gestation day (GD) 6 up to and including GD 20 at concentrations of 50, 300 and 900 ppm. Verification of the target concentrations were performed throughout exposure. Maternal rats were observed for manifestation of clinical signs before, during and after exposure. Body weights of the parental female animals was recorded on gestation days (GD) 0, 6, 9, 12, 15, 18 and 21. Food consumed for each mated female was measured. The females were killed by exsanguination after isofluorane anaesthesia on GD 21 and examined for gross abnormalities, organ weights and uterine content. Fetuses were examined for external alterations and sacrificed by hypothermia. Subsequently, approximately half of the fetuses of each litter were examined for soft tissue anomalies and the other half were examined for skeletal abnormalities.
The overall average actual concentrations (± standard deviation) of hexafluoropropene in the test atmospheres, as determined by total carbon analysis, were 50 (± 0.7), 302 (± 3) and 901 (± 16) ppm for the low-, mid- and high-concentration, respectively. These concentrations were close to the respective target concentrations of 50, 300 and 900 ppm. At gestation day 21 caesarean section was performed, dams were examined macroscopically and reproductive organs, liver and kidney were weighed. Fetuses and placentas were weighed and fetuses were examined externally. The exposure to the test material was well tolerated at low and mid concentration and did not induce treatment-related changes in general condition. Females in the high concentration group frequently showed piloerection. Statistically significantly reduced body weight and body weight gain was observed in the females of the mid and high concentration group. Mean body weight at the end of gestation in the mid concentration group was less than 5% lower as compared to the control group. This was considered a slightly lower body weight and not considered to be adverse. Mean body weight at the end of gestation in the high concentration group was 15% lower as compared to the control group. This was considered an adverse and treatment-related effect. Concentration related lowered mean food consumption was observed in the mid and high concentration groups for intervals 6-9 days and later. Uterus weight for both full and empty uterus was lower in the high concentration group, which could be related to maternal toxicity. Organ weights revealed an increase in weight of the kidneys, visible already at the 50 ppm concentration. Macroscopic pathologic observation of the kidneys showed enlargement and discoloration in the 900 ppm group. In combination with the effects on kidney weight this was considered a treatment-related and adverse effect.
The slightly lower body weight and feed intake observed in the 300 ppm group were considered related to treatment, but in view of the severity considered not adverse. The observed effects on body weight, feed intake and kidney weight (supported by macroscopic observations in the 900 ppm group) were considered related to treatment and adverse. Therefore, the No Observed Adverse Effect Concentration(NOAEC)for maternal toxicity was placed at 300 ppm.
Mean fetus weight was statistically significantly lower in the mid and high concentration groups. A concentration-dependent effect was observed with less than 5% lower fetus weight in the 300 ppm group and more than 15% lower fetus weight in the 900 ppm group as compared to the control group. Furthermore, a number of skeletal observations indicative of retardation in ossification were noted. With some exceptions, statistical significance was mostly confined to the high-concentration group. The retardation in ossification is considered to be related to the lower fetus weight observed.
The slight effect on fetus weight and ossification in the 300 ppm group was considered related to treatment, but in view of the severity were not considered to be biologically relevant and, therefore, not adverse. The effect on fetus weight, accompanied by a retardation in ossification observed in the 900 ppm group was considered adverse. Therefore NOAEC for developmental toxicity was placed at 300 ppm.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
